跳轉至內容
Merck
全部照片(1)

重要文件

C2385000

氯硝西泮

European Pharmacopoeia (EP) Reference Standard

同義詞:

5-(2-Chlorophenyl)-7-nitro-3H-1,4-benzodiazepin-2(1H)-one

登入查看組織和合約定價


About This Item

經驗公式(希爾表示法):
C15H10ClN3O3
CAS號碼:
分子量::
315.71
MDL號碼:
分類程式碼代碼:
41116107
PubChem物質ID:
NACRES:
NA.24

等級

pharmaceutical primary standard

API 家族

clonazepam

製造商/商標名

EDQM

藥物控制

USDEA Schedule IV; regulated under CDSA - not available from Sigma-Aldrich Canada; psicótropo (Spain); Decreto Lei 15/93: Tabela IV (Portugal)

應用

pharmaceutical (small molecule)

形式

neat

儲存溫度

2-8°C

SMILES 字串

Clc1ccccc1C2=NCC(=O)Nc3ccc(cc23)N(=O)=O

InChI

1S/C15H10ClN3O3/c16-12-4-2-1-3-10(12)15-11-7-9(19(21)22)5-6-13(11)18-14(20)8-17-15/h1-7H,8H2,(H,18,20)

InChI 密鑰

DGBIGWXXNGSACT-UHFFFAOYSA-N

尋找類似的產品? 前往 產品比較指南

一般說明

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

應用

Clonazepam EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

包裝

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

其他說明

Sales restrictions may apply.

象形圖

Exclamation mark

訊號詞

Warning

危險聲明

危險分類

Aquatic Chronic 3 - STOT SE 3

標靶器官

Central nervous system

儲存類別代碼

11 - Combustible Solids

水污染物質分類(WGK)

WGK 1

閃點(°F)

Not applicable

閃點(°C)

Not applicable


從最近期的版本中選擇一個:

分析證明 (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our 文件 section.

如果您需要協助,請聯絡 客戶支援

已經擁有該產品?

您可以在文件庫中找到最近購買的產品相關文件。

存取文件庫

客戶也查看了

G Chouinard
The Journal of clinical psychiatry, 48 Suppl, 29-37 (1987-10-01)
This is a report on the efficacy of clonazepam in the treatment of acute mania. The advantages of clonazepam over standard neuroleptics are its rapidity of action, its lack of toxicity, and, particularly important, the fact that it does not
Jerrold F Rosenbaum
The Journal of clinical psychiatry, 65 Suppl 5, 3-6 (2004-04-14)
The pathophysiology of anxiety disorders is not clearly understood; therefore, clinical observation, case reports, and case reviews continue to enhance physicians' understanding of disease and treatment mechanisms. At Massachusetts General Hospital (MGH), physicians and researchers are guided by the recognition
Shigeru Morishita
Human psychopharmacology, 24(3), 191-198 (2009-03-31)
Clonazepam, first used for seizure disorders, is now increasingly used to treat affective disorders. We summarize the use of clonazepam to improve the management of depression. Clonazepam is useful for treatment-resistant and/or protracted depression, as well as for acceleration of
Raffaele Ferri et al.
Sleep medicine, 14(1), 24-29 (2012-10-27)
To analyze the differences in sleep structure and nocturnal motor activity between drug-free REM sleep behavior disorder (RBD) patients and those under therapy with clonazepam, and to evaluate the long-term longitudinal changes under continued therapy with clonazepam. Fifty-seven consecutive iRBD
Stuart J McCarter et al.
Sleep medicine, 14(3), 237-242 (2013-01-29)
REM sleep behavior disorder (RBD) is usually characterized by potentially injurious dream enactment behaviors (DEB). RBD treatment aims to reduce DEBs and prevent injury, but outcomes require further elucidation. We surveyed RBD patients to describe longitudinal treatment outcomes with melatonin

我們的科學家團隊在所有研究領域都有豐富的經驗,包括生命科學、材料科學、化學合成、色譜、分析等.

聯絡技術服務